Archives of Clinical Infectious Diseases

Published by: Kowsar

Nitazoxanide and Doxycycline Sensitivity Among Metronidazole Resistant Helicobacter pylori Isolates from Patients with Gastritis

Ali Baradaran Moghaddam 1 , Nour Amirmozafari 2 , Shahla Mansouri 3 , Nastaran Farzi 4 , Naser Ebrahimi-Daryani 5 , Masoud Alebouyeh 4 , * and Mohammad Reza Zali 6
Authors Information
1 Microbiology Department, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
2 Microbiology Department, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
3 Microbiology Department, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
4 Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5 Department of Gastroenterology, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
6 Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Article information
  • Archives of Clinical Infectious Diseases: January 2018, 13 (1); e66693
  • Published Online: February 2, 2018
  • Article Type: Research Article
  • Received: September 29, 2016
  • Revised: April 23, 2017
  • Accepted: May 1, 2017
  • DOI: 10.5812/archcid.66693

To Cite: Baradaran Moghaddam A, Amirmozafari N, Mansouri S, Farzi N, Ebrahimi-Daryani N, et al. Nitazoxanide and Doxycycline Sensitivity Among Metronidazole Resistant Helicobacter pylori Isolates from Patients with Gastritis, Arch Clin Infect Dis. 2018 ; 13(1):e66693. doi: 10.5812/archcid.66693.

Abstract
Copyright © 2018, Archives of Clinical Infectious Diseases. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Haag S, Talley NJ, Holtmann G. Symptom patterns in functional dyspepsia and irritable bowel syndrome: relationship to disturbances in gastric emptying and response to a nutrient challenge in consulters and non-consulters. Gut. 2004;53(10):1445-51. doi: 10.1136/gut.2003.030049. [PubMed: 15361493].
  • 2. Wotherspoon AC. Gastric lymphoma of mucosa-associated lymphoid tissue and Helicobacter pylori. Annu Rev Med. 1998;49:289-99. doi: 10.1146/annurev.med.49.1.289. [PubMed: 9509264].
  • 3. Covacci A, Telford JL, Del Giudice G, Parsonnet J, Rappuoli R. Helicobacter pylori virulence and genetic geography. Science. 1999;284(5418):1328-33. doi: 10.1126/science.284.5418.1328. [PubMed: 10334982].
  • 4. Öztürk E. Diagnostic methods of Helicobacter pylori infection. Gulhane Med J. 2008;50(1):60-4.
  • 5. Wu H, Shi XD, Wang HT, Liu JX. Resistance of helicobacter pylori to metronidazole, tetracycline and amoxycillin. J Antimicrob Chemother. 2000;46(1):121-3. doi: 10.1093/jac/46.1.121. [PubMed: 10882700].
  • 6. Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut. 2007;56(10):1353-7. doi: 10.1136/gut.2007.125658. [PubMed: 17566020].
  • 7. Basu PP, Rayapudi K, Pacana T, Shah NJ, Krishnaswamy N, Flynn M. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol. 2011;106(11):1970-5. doi: 10.1038/ajg.2011.306. [PubMed: 21989146].
  • 8. Ramos-Soriano AG, Black J. Nitazoxanide Use as Part of an Empiric Multi-Drug Regimen in Treating Children with Suspected Helicobacter pylori Infection. Case Rep Gastroenterol. 2015;9(1):36-42. doi: 10.1159/000375116. [PubMed: 25759631].
  • 9. Doumbo O, Rossignol JF, Pichard E, Traore H, Dembele MM, Diakite M, et al. Nitazoxanide in the treatment of cryptosporidiosis in 24 AIDS patients with chronic diarrhea in Mali. Am J Trop Med Hyg. 1997;26(56):637-9.
  • 10. Dubreuil L, Houcke I, Mouton Y, Rossignol JF. In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob Agents Chemother. 1996;40(10):2266-70. [PubMed: 8891127].
  • 11. Barza M, Schiefe RT. Antimicrobial spectrum, pharmacology and therapeutic use of antibiotics. Part 1: tetracyclines. Am J Hosp Pharm. 1977;34(1):49-57. [PubMed: 318799].
  • 12. Meier J. Doxycycline in respiratory tract infections. A review of a multi-centre trial. Chemotherapy. 1975;21 Suppl 1:130-5. doi: 10.1159/000221899. [PubMed: 239837].
  • 13. Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther. 2005;27(9):1329-42. doi: 10.1016/j.clinthera.2005.09.005. [PubMed: 16291409].
  • 14. Shahabimehr M, Alebouyeh M, Farzi N, Mahboubi A, Taslimi R, Zali MR. Resistance rate and minimum inhibitory concentration of metronidazole among Helicobacter pylori strains in Tehran, Iran. Arch Clin Infect Dis. 2016;11(2). doi: 10.5812/archcid.34478.
  • 15. Clinical and Laboratory Standard Institute . Performance standards for antimicrobial susceptibility testing; 17th informational supplement. Wayne PA , editor. 2007.
  • 16. Hunt RH, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, van der Merwe S, et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis. 2011;20(3):299-304. [PubMed: 21961099].
  • 17. Novis BH, Gabay G, Naftali T. Helicobacter pylori: the Middle East scenario. Yale J Biol Med. 1998;71(2):135-41. [PubMed: 10378359].
  • 18. Savari M, Abdollahi H, Zahedi MJ, Darvish Moghadam S, Hayat Bakhsh Abasi M. Antibiotic-resistance patterns of Helicobacter pylori isolates obtained from patients in Kerman-2009 [In Persian]. J Kerman Univ Med Sci. 2011;18(1):73-82.
  • 19. Khedmat H, Karbasi-Afshar R, Agah S, Taheri S. Helicobacter pylori Infection in the general population: A Middle Eastern perspective. Caspian J Intern Med. 2013;4(4):745-53. [PubMed: 24294467].
  • 20. Moradi A, Rashidipour A. Seroepidemiology of Helicobacter pylori infection in Semnan [In Persian]. J Koomesh. 2000;1(3):53-7.
  • 21. Mokhtari M. Evaluation of antibody of Helicobacter pylori infection in preschool children in Isfahan. Iran J Gastroenterol. 2002;(36):6.
  • 22. Kargar M, Souod N, Doosti A, Ghorbani-Dalini S. Prevalence of Helicobacter pylori vacuolating cytotoxin A gene as a predictive marker for different gastrodoudenal diseases. Arch Clin Infect Dis. 2011;6(2):85-9.
  • 23. Sheikholeslami H, Ghasemibarghi R, Moosavi H. Comparison of prevalence of Helicobacter pylori infection in urban and rural areas of Qazvin (2002) [In Persian]. J Qazvin Univ Med Sci. 2004;8(3):47-51.
  • 24. Vaziri F, Najar Peerayeh S, Alebouyeh M, Molaei M, Maghsoudi N, Zali MR. Determination of Helicobacter pylori CagA EPIYA types in Iranian isolates with different gastroduodenal disorders. Infect Genet Evol. 2013;17:101-5. doi: 10.1016/j.meegid.2013.03.048. [PubMed: 23567822].
  • 25. Yadegar A, Alebouyeh M, Zali MR. Analysis of the intactness of Helicobacter pylori cag pathogenicity island in Iranian strains by a new PCR-based strategy and its relationship with virulence genotypes and EPIYA motifs. Infect Genet Evol. 2015;35:19-26. doi: 10.1016/j.meegid.2015.07.026. [PubMed: 26205689].
  • 26. Bohr UR, Primus A, Zagoura A, Glasbrenner B, Wex T, Malfertheiner P. A group-specific PCR assay for the detection of Helicobacteraceae in human gut. Helicobacter. 2002;7(6):378-83. doi: 10.1046/j.1523-5378.2002.00113.x. [PubMed: 12485125].
  • 27. Ierardi E, Giorgio F, Losurdo G, Di Leo A, Principi M. How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography? World J Gastroenterol. 2013;19(45):8168-80. doi: 10.3748/wjg.v19.i45.8168. [PubMed: 24363506].
  • 28. Shokrzadeh L, Alebouyeh M, Mirzaei T, Farzi N, Zali MR. Prevalence of multiple drug-resistant Helicobacter pylori strains among patients with different gastric disorders in Iran. Microb Drug Resist. 2015;21(1):105-10. doi: 10.1089/mdr.2014.0081. [PubMed: 25303151].
  • 29. Rafeey M, Ghotaslou R, Nikvash S, Hafez AA. Primary resistance in Helicobacter pylori isolated in children from Iran. J Infect Chemother. 2007;13(5):291-5. doi: 10.1007/s10156-007-0543-6. [PubMed: 17982716].
  • 30. Haghi Tomatari F, Mobarez A, Amini M, Hosseini D, Abadi A. Helicobacter pylori resistance to metronidazole and clarithromycin in dyspeptic patients in Iran. Iran Red Crescent Med J. 2010;12(4):409-12.
  • 31. Mohammadi M, Doroud D, Mohajerani N, Massarrat S. Helicobacter pylori antibiotic resistance in Iran. World J Gastroenterol. 2005;11(38):6009-13. doi: 10.3748/wjg.v11.i38.6009. [PubMed: 16273615].
  • 32. Falsafi T, Mobasheri F, Nariman F, Najafi M. Susceptibilities to different antibiotics of Helicobacter pylori strains isolated from patients at the pediatric medical center of Tehran, Iran. J Clin Microbiol. 2004;42(1):387-9. doi: 10.1128/JCM.42.1.387-389.2004. [PubMed: 14715786].
  • 33. Siavoshi F, Saniee P, Latifi-Navid S, Massarrat S, Sheykholeslami A. Increase in resistance rates of H. pylori isolates to metronidazole and tetracycline--comparison of three 3-year studies. Arch Iran Med. 2010;13(3):177-87. [PubMed: 20433221].
  • 34. Mirzaei N, Poursina F, Faghri J, Talebi M, Khataminezhad MR, Hasanzadeh A, et al. Prevalence of resistance of Helicobacter pylori strains to selected antibiotics in Isfahan, Iran. Jundishapur J Microbiol. 2013;6(5). doi: 10.5812/jjm.6342.
  • 35. Francesco VD, Zullo A, Hassan C, Giorgio F, Rosania R, Ierardi E. Mechanisms of Helicobacter pylori antibiotic resistance: An updated appraisal. World J Gastrointest Pathophysiol. 2011;2(3):35-41. doi: 10.4291/wjgp.v2.i3.35. [PubMed: 21860834].
  • 36. Talebi Bezmin Abadi A, Mobarez AM, Taghvaei T, Wolfram L. Antibiotic resistance of Helicobacter pylori in Mazandaran, North of Iran. Helicobacter. 2010;15(6):505-9. doi: 10.1111/j.1523-5378.2010.00795.x. [PubMed: 21073606].
  • 37. Wu JY, Kim JJ, Reddy R, Wang WM, Graham DY, Kwon DH. Tetracycline-resistant clinical Helicobacter pylori isolates with and without mutations in 16S rRNA-encoding genes. Antimicrob Agents Chemother. 2005;49(2):578-83. doi: 10.1128/AAC.49.2.578-583.2005. [PubMed: 15673736].
  • 38. Cammarota G, Martino A, Pirozzi G, Cianci R, Branca G, Nista EC, et al. High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. Aliment Pharmacol Ther. 2004;19(7):789-95. doi: 10.1111/j.1365-2036.2004.01910.x. [PubMed: 15043520].
  • 39. Loo VG, Sherman P, Matlow AG. Helicobacter pylori infection in a pediatric population: in vitro susceptibilities to omeprazole and eight antimicrobial agents. Antimicrob Agents Chemother. 1992;36(5):1133-5. doi: 10.1128/AAC.36.5.1133. [PubMed: 1510406].
  • 40. Megraud F, Occhialini A, Rossignol JF. Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole. Antimicrob Agents Chemother. 1998;42(11):2836-40. [PubMed: 9797212].
  • 41. Guttner Y, Windsor HM, Viiala CH, Dusci L, Marshall BJ. Nitazoxanide in treatment of Helicobacter pylori: a clinical and in vitro study. Antimicrob Agents Chemother. 2003;47(12):3780-3. doi: 10.1128/AAC.47.12.3780-3783.2003. [PubMed: 14638482].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments